- Home
- CDE vs FOLD Comparison
CDE vs FOLD Comparison
Compare CDE & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDE
- FOLD
- Stock Information
- Founded
- CDE 1928
- FOLD 2002
- Country
- CDE United States
- FOLD United States
- Employees
- CDE N/A
- FOLD N/A
- Industry
- CDE Precious Metals
- FOLD Biotechnology: Pharmaceutical Preparations
- Sector
- CDE Basic Materials
- FOLD Health Care
- Exchange
- CDE Nasdaq
- FOLD Nasdaq
- Market Cap
- CDE 2.5B
- FOLD 2.9B
- IPO Year
- CDE N/A
- FOLD 2007
- Fundamental
- Price
- CDE $5.46
- FOLD $9.19
- Analyst Decision
- CDE Strong Buy
- FOLD Strong Buy
- Analyst Count
- CDE 4
- FOLD 9
- Target Price
- CDE $8.00
- FOLD $17.00
- AVG Volume (30 Days)
- CDE 22.5M
- FOLD 2.3M
- Earning Date
- CDE 02-19-2025
- FOLD 02-19-2025
- Dividend Yield
- CDE N/A
- FOLD N/A
- EPS Growth
- CDE N/A
- FOLD N/A
- EPS
- CDE 0.15
- FOLD N/A
- Revenue
- CDE $1,054,006,000.00
- FOLD $528,294,999.00
- Revenue This Year
- CDE $32.37
- FOLD $34.88
- Revenue Next Year
- CDE $44.71
- FOLD $20.78
- P/E Ratio
- CDE $36.40
- FOLD N/A
- Revenue Growth
- CDE 28.35
- FOLD 32.29
- 52 Week Low
- CDE $2.42
- FOLD $8.79
- 52 Week High
- CDE $7.72
- FOLD $14.02
- Technical
- Relative Strength Index (RSI)
- CDE 31.96
- FOLD 38.52
- Support Level
- CDE $6.82
- FOLD $9.32
- Resistance Level
- CDE $7.33
- FOLD $10.00
- Average True Range (ATR)
- CDE 0.39
- FOLD 0.33
- MACD
- CDE -0.15
- FOLD -0.05
- Stochastic Oscillator
- CDE 1.68
- FOLD 17.35
About CDE Coeur Mining Inc.
Coeur Mining Inc is a metals producer focused on mining precious minerals in the Americas. It is involved in the discovery and mining of gold and silver and generates the vast majority of revenue from the sale of these precious metals. The operating mines of the company are palmarejo, Rochester, Wharf, and Kensington. Its projects are located in the United States, Canada Mexico, and North America.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.